Cihui Chen

Cihui Chen


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2014 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
WLWeidong Li
Weidong Li
CCCihui Chen
Cihui Chen
SSShakir M Saud
Shakir M Saud
LGLiang Geng
Liang Geng
GZGe Zhang
Ge Zhang
BHBaojin Hua
Baojin Hua
Lung cancer is one of the leading causes of cancer-related mortality worldwide. Conventional chemotherapy and radiotherapy are the primary therapeutic methods for lung cancer with the use of combination therapies gaining popularity. The frequency and duration of treatment, as well as, managing lung cancer by targeting multiple aspects of cancer biology is often limited by toxicity to the patient. There are many naturally occurring anticancer agents that have a high degree of efficacy and low toxicity, offering a viable and safe approach for the treatment of lung cancer. The herbs traditionally used in Chinese medicine for anticancer treatment offer great potential to enhance the efficacy of conventional therapy. In this study, we evaluated the synergistic effects of Fei-Liu-Ping (FLP) ointment in treating lung cancer; a known anticancer Chinese herbal based formula.

29 May 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MCMengqi Cheng
Mengqi Cheng
QSQianhui Sun
Qianhui Sun
HDHua Duan
Hua Duan
CCCihui Chen
Cihui Chen
Background: The pre-metastatic niche (PMN) represents the microenvironment established in target organs before primary tumor metastasis, playing a crucial role in organ-specific metastasis. Understanding and preventing PMN formation holds promise for enhancing immunotherapy efficacy and reducing cancer-related mortality. Despite the significance of this field, a comprehensive bibliometric analysis is lacking. This study aims to identify global research trends and hotspots in PMN through a systematic bibliometric evaluation, providing a foundation for future advancements in this field.Methods: Publications related to PMN research from 2005 to 2024 were retrieved from the Web of Science Core Collection database. Bibliometric analyses and visualizations were conducted using VOSviewer, CiteSpace, Microsoft Excel, ArcGIS, Scimago Graphica, and Microsoft Charticulator.Results: The study included 1,303 publications authored by 7,955 researchers from 1,627 institutions across 62 countries, with articles published in 400 journals. China and the United States emerged as central contributors to global PMN research. China has led in publication volume and institutional representation, while the United States has produced the most high-quality papers and impactful authors. Cancers published the most PMN-related papers, while Cancer Research had the most citations and co-citations. Professor David Lyden of Cornell University, USA, was identified as the most influential scholar in the field. Analysis of references and keywords suggests future research will focus on metastatic organotropism, extracellular vesicles, innate immunocytes (e.g., macrophages and neutrophils), and immunotherapy.Conclusion: This bibliometric study represents the first comprehensive analysis of global scientific output in PMN research over the past two decades. By summarizing the current status and identifying trends in the field, this study provides valuable insights and a reference point for researchers aiming to prevent and treat tumor metastasis effectively.

4 June 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
HDHua Duan
Hua Duan
MCMengqi Cheng
Mengqi Cheng
QSQianhui Sun
Qianhui Sun
CCCihui Chen
Cihui Chen
Background: Peritoneal malignancies (PM) represent a group of highly heterogeneous tumors associated with poor prognosis and limited effective treatment options. Recent studies have demonstrated significant progress in understanding the tumor microenvironment (TME) of PM. However, no bibliometric analysis focusing on PM and TME has been conducted. This study aims to provide a comprehensive assessment of the current research landscape and to identify key areas of interest and emerging trends in this field from a bibliometric perspective.Methods: Publications related to the TME in PM from 2010 to 2024 were retrieved from the Web of Science Core Collection database. Microsoft Excel, VOSviewer, CiteSpace, and R package “bibliometrix” were used to perform the visualization analysis.Results: A total of 862 papers from 56 countries were included. Both annual publication counts and citations have increased steadily over time. The United States of America (USA) contributed the highest number of publications and demonstrated the greatest impact, followed by China and Japan. The University of Texas MD Anderson Cancer Center, Sichuan University and Fudan University were identified as the leading research institutions. Four of the top five most prolific authors are from Japan, including Kajiyama Hiroaki, Yashiro Masakazu, Fushida Sachio and Kinoshita Jun. Cancers published the largest number of articles, with 56 publications, while Cancer research was the most frequently co-cited journal. Reference and keyword burst detection revealed that research hotspots include cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, immunotherapy, tumor-associated macrophages, cancer-associated fibroblast and endothelial growth factor.Conclusions: This study summarizes recent research frontiers and hotspots regarding the TME in PM and provided valuable references for future investigations. Immunotherapy targeting the TME is likely to become a major research direction.

28 October 2026 in Discover Oncology
Verified
Journal Article
Open access
PDF file
XLXinhuan Lv
Xinhuan Lv
JLJia Li
Jia Li
MCMengqi Cheng
Mengqi Cheng
QSQianhui Sun
Qianhui Sun
HCHanxiao Chen
Hanxiao Chen
HDHua Duan
Hua Duan
Background Myeloid-derived suppressor cells (MDSCs) are pivotal immunosuppressive cells within the tumor microenvironment (TME) that promote tumor progression and mediate resistance to immunotherapy. Despite sustained research interest, a comprehensive bibliometric overview of global research output in this field has not been systematically summarized. Methods Publications were collected of MDSCs within TME from 2015 to 2025 by the Web of Science Core Collection and Scopus. Bibliometric analyses were performed using VOSviewer, CiteSpace, and bibliometrix to characterize annual publication trends, leading countries, institutions, authors, core journals, co‑cited references, thematic evolution, and emerging research frontiers. Results A total of 5,967 publications were included in this study. Annual publications increased nonlinearly, peaked in 2022, and subsequently stabilized with mild fluctuations. China and the United States (USA) were the dominant contributors, with the USA displaying superior citation impact and international collaboration. Fudan University, Sun Yat‑sen University, and the University of Texas MD Anderson Cancer Center represented the most productive and influential institutions. Researchers including Gabrilovich DI, Bronte V, and Veglia F constituted the intellectual backbone of the field, with their landmark reviews displaying the strongest citation bursts. Frontiers in Immunology published the most articles and the highest co-cited journal was Cancer Research. TME, immunotherapy and MDSCs emerged as the three central themes. The field has undergone a paradigm shift from simplified MDSCs classification toward single‑cell sequencing, multi‑omics, subset heterogeneity, immune infiltration, and immune evasion. Conclusions MDSCs are central regulators of the immunosuppressive TME and key drivers of immunotherapy resistance. Clinical translation of MDSC‑targeted therapies remains limited by tumor heterogeneity, TME complexity, and suboptimal combination strategies. Future research should emphasize standardized MDSC identification, context‑dependent regulatory mechanisms and rational combinatorial therapeutic designs to bridge the translational gap and facilitate clinical implementation of MDSC‑targeted cancer immunotherapy. Clinical trial registration Not applicable. This study is a bibliometric analysis and does not report on any clinical trial. The clinical trials (including NCT06439888) mentioned in the Discussion section were identified from the public registry ClinicalTrials.gov for contextual discussion and are not part of the authors’ own research.